ArticleJournal of clinical microbiology2020
The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States.
Article in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 38 citations in OpenAlex.
- Antiphospholipid antibodies in acute and post-treatment Lyme disease.Infection and immunity · 2026Article
- Single-step immunoblot tests with recombinant protein antigens for detecting IgG and IgM antibodies in Lyme disease.Microbiology spectrum · 2026Article
- Evaluation of standard and modified two-tiered testing algorithms using well-characterized early Lyme disease samples.Journal of clinical microbiology · 2026Article
- Testing the capacity of humanized immune system mice to induce a protective antibody response against the Lyme disease pathogen.Microbiology spectrum · 2026Article
- Adaptation of custom capture sequencing panels to the Oxford Nanopore MinION platform.Molecular biology reports · 2026Article
- The multiplexed single-tier InBios Lyme Detect Multiplex ELISA is more sensitive than standard two-tier tests in the early stages of Lyme disease.Journal of clinical microbiology · 2025Article
- A novel single-tier serologic test to diagnose all stages of Lyme disease.Journal of clinical microbiology · 2025Article
- Class and isotype of VlsE-specific antibody differentiates Lyme disease stage.Journal of clinical microbiology · 2025Article
- Article
- External Validation of Raman Spectroscopy for Lyme Disease Diagnostics.Journal of biophotonics · 2025Article
- Lyme Disease Biobank: 10 years of 3 month follow-up visits from 2014 to 2023.Frontiers in medicine · 2025Article
- Serologic biomarker discovery for differentiating Lyme disease from diseases with similar clinical symptoms using broad profiling of antibody binding.Frontiers in immunology · 2025Article
- Preliminary Results of Iran Premature Coronary Artery Disease (IPAD study) and Implementation of IPAD Biobank: A Case-Control Study.Archives of Iranian medicine · 2024Article
- Rapid single-tier serodiagnosis of Lyme disease.Nature communications · 2024Article
- Article
- Host glycosylation of immunoglobulins impairs the immune response to acute Lyme disease.EBioMedicine · 2024Article
- Highly heterogenous humoral immune response in Lyme disease patients revealed by broad machine learning-assisted antibody binding profiling with random peptide arrays.Frontiers in immunology · 2024Article
- Does Biological Sex Matter in Lyme Disease? The Need for Sex-Disaggregated Data in Persistent Illness.International journal of general medicine · 2023Article
- The Spectrum of Erythema Migrans in Early Lyme Disease: Can We Improve Its Recognition?Cureus · 2022Article
- Capture Sequencing Enables Sensitive Detection of Tick-Borne Agents in Human Blood.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lyme disease (LD) is an increasing public health problem. Current laboratory testing is insensitive in early infection, the stage at which appropriate treatment is most effective in preventing disease sequelae. The Lyme Disease Biobank (LDB) collects samples from individuals with symptoms consistent with early LD presenting with or without erythema migrans (EM) or an annular, expanding skin lesion and uninfected individuals from areas of endemicity. Samples were collected from 550 participants (298 cases and 252 controls) according to institutional review board-approved protocols and shipped to a centralized biorepository. Testing was performed to confirm the presence of tick-borne pathogens by real-time PCR, and a subset of samples was tested for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.